A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer
Related Posts
Tang Z, Zhao J, Li Y, Tomer S, Selvaraju M, Tien N, Sun D, Johnson DK, Zhen A, Li P, Wang J. Structural Evaluations of[...]
Li YR, Zhou Y, Yu J, Kim YJ, Li M, Lee D, Zhou K, Chen Y, Zhu Y, Wang YC, Li Z, Yu Y, Dunn[...]
Wander SA, Bardia A. Cracking the Genomic Code of CDK4/6 Inhibitor Resistance. Clin Cancer Res. 2024 May 15;30(10):2008-2010. doi: 10.1158/1078-0432.CCR-23-3413. PMID: 38319645.